Kamada

Focus: Kamada is a plasma-derived biologics company headquartered in Israel's Negev region, focused on therapeutic development across metabolic, infectious, and rare diseases. The company operates a diversified pipeline with programs spanning Phase 1 through Phase 4 development.

Metabolic Diseases Infectious Diseases Rare Diseases

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About Kamada

AI assessmentNot Hiring

No open roles listed right now. Follow Kamada to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Mid-stage

2 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

Glassia

Acute-graft-versus-host Disease

N/A

Clinical Trials (1)

NCT03172455Early Access Program Using Alpha 1 Antitrypsin Infusion for Patients With Steroid Refractory Acute GvHD After Hematopoietic Stem Cell Transplantation (HSCT)

N/A

Help build intelligence for Kamada

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Diverse pipeline across 16 clinical programs spanning Phase 1/2 through Phase 4, providing exposure to multiple therapeutic modalities and disease areas
Specialized focus on plasma-derived biologics and immunoglobulins positions Kamada in a differentiated niche with limited direct competitors
Active development in high-impact areas including alpha-1 antitrypsin deficiency, graft-versus-host disease, and rabies immunization

Watch Out For

Zero current job openings reported suggests potential hiring freeze or organizational contraction
Missing financial data (revenue, funding, cash position) creates visibility gap on company stability and growth trajectory

Generated by Claude from Kamada's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Alpha-1 Antitrypsin 40mg

Type 1 Diabetes Mellitus

Phase 1/2

Clinical Trials (1)

NCT01304537Study of the Safety and Efficacy of Intravenous Alpha-1 Antitrypsin in Type 1 Diabetes Mellitus

Phase 1/2

Kamada Anti-SARS-CoV-2

Covid19

Phase 1/2

Clinical Trials (1)

NCT04550325Safety, PK and PD of Kamada Anti-SARS-CoV-2 in COVID-19

Phase 1/2

Alpha-1 Antitrypsin

New Onset Type-1 Diabetes

Phase 2

Clinical Trials (1)

NCT02005848Phase II Study to Evaluate the Efficacy and Safety of Glassia® in Type-1 Diabetes

Phase 2

AAT

Type 1 Diabetes

Phase 2

Clinical Trials (1)

NCT01661192Long Term Treatment Effect of the Safety, Tolerability and Efficacy of AAT in Type 1 Diabetes

Phase 2

Aerosolized, human, plasma-derived Alpha-1 Antitrypsin

Cystic Fibrosis

Phase 2

Clinical Trials (1)

NCT00499837Phase II Study of the Safety and Efficacy of Inhaled Alpha-1 Antitrypsin (AAT ) in Cystic Fibrosis Patients

Phase 2

Kamada-AAT for Inhalation, 80mg

Alpha-1 Antitrypsin Deficiency

Phase 2

Clinical Trials (1)

NCT02001688Phase II, Safety and Efficacy Study of Kamada-alpha-1-antitrypsin (AAT) for Inhalation"

Phase 2

GLASSIA® and Institution standard of care

Transplantation, Lung Rejection

Phase 2

Clinical Trials (1)

NCT02614872Study to Evaluate the Safety and Efficacy of Intravenous Glassia® Treatment in Lung Transplantation

Phase 2

Kamada AAT for inhalation

Emphysema

Phase 2/3

Clinical Trials (1)

NCT01217671International Study Evaluating the Safety and Efficacy of Inhaled, Human, Alpha-1 Antitrypsin (AAT) in Alpha-1 Antitrypsin Deficient Patients With Emphysema

Phase 2/3

Active rabies vaccine

Rabies

Phase 2/3

Clinical Trials (1)

NCT02040090Phase II/III Study of the Safety and Effectiveness of HRIG With Active Rabies Vaccine in Healthy Subjects

Phase 2/3

GLASSIA

Graft Versus Host Disease

Phase 2/3

Kamada-API

Alpha 1-Antitrypsin Deficiency